Valuation : EnteroMedics Inc

Market Cap 15.58M 13.41M 12.61M 11.52M 21.56M 1.47B 21.62M 149M 57.84M 755M 58.51M 57.23M 2.43B P/E 2026 *
-3.89x
P/E 2027 * -2.78x
Enterprise Value 15.58M 13.41M 12.61M 11.52M 21.56M 1.47B 21.62M 149M 57.84M 755M 58.51M 57.23M 2.43B EV / Sales 2026 *
117x
EV / Sales 2027 * 77.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 133K 115K 108K 98.61K 184K 12.59M 185K 1.28M 495K 6.46M 501K 490K 20.81M 200K 172K 162K 148K 277K 18.88M 277K 1.91M 742K 9.69M 751K 735K 31.21M
Net income -4M -3.44M -3.24M -2.96M -5.53M -378M -5.55M -38.27M -14.85M -194M -15.02M -14.69M -624M -7.85M -6.75M -6.35M -5.8M -10.86M -741M -10.88M -75.06M -29.13M -380M -29.46M -28.82M -1.22B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-